SEARCH

SEARCH BY CITATION

References

  • 1
    Birmaher B, Ryan ND, Williamson DE et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J. Am. Acad. Child Adolesc. Psychiatry 1996; 35: 14271439.
  • 2
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, DC: American Psychiatric Association, 2013.
  • 3
    Merikangas KR, He M, Burstein M et al. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Study – Adolescent Supplement (NCS-A). J. Am. Acad. Child Adolesc. Psychiatry 2010; 49: 980989.
  • 4
    Biederman J, Faraone S, Mick E, Lelon E. Psychiatric comorbidity among referred juveniles with major depression: fact or artifact? J. Am. Acad. Child Adolesc. Psychiatry 1995; 34: 579590.
  • 5
    Gould MS, Greenberg T, Velting DM, Shaffer D. Youth suicide risk and preventive interventions: a review of the past 10 years. J. Am. Acad. Child Adolesc. Psychiatry 2003; 42: 386405.
  • 6
    Melvin GA, Dudley AL, Gordon MS, Ford S, Taffe J, Tonge BJ. What happens to depressed adolescents? A follow-up study into early adulthood. J. Affect. Disord. 2013; 151: 298305.
  • 7
    Dunn V, Goodyer IM. Longitudinal investigation into childhood- and adolescent-onset depression psychiatric outcomes in early adulthood. Br. J. Psychiatry 2006; 188: 216222.
  • 8
    Curry J, Silva S, Rohde P et al. Recovery and recurrence following treatment for adolescent major depression. Arch. Gen. Psychiatry 2011; 68: 263269.
  • 9
    Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 96: 369374.
  • 10
    Anderson IM. Meta-analytical studies on new antidepressants. Br. Med. Bull. 2001; 57: 161178.
  • 11
    Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J. Am. Acad. Child Adolesc. Psychiatry 2010; 49: 10011010.
  • 12
    Efron D, Hiscock H, Sewell JR et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003; 111: 372375.
  • 13
    Nash J, Nutt D. Antidepressants. Psychiatry 2007; 6: 289294.
  • 14
    Stahl SM. Not so selective serotonin reuptake inhibitors. J. Clin. Psychiatry 1998; 59: 343344.
  • 15
    Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 1997; 36: 725736.
  • 16
    Ellis PM, Hickie I, Smith DAR. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust. N. Z. J. Psychiatry 2004; 38: 389407.
  • 17
    U.S. Food and Drug Administration. Labeling change request letter for antidepressant medications. Silver Spring, MD: FDA, 2004. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096352.htm [accessed November 2013].
  • 18
    Mann JJ, Emslie G, Baldessarini RJ et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31: 473492.
  • 19
    Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; 2: CD002317.
  • 20
    Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog. Neuropsychopharmacol Biol. Psychiatry 1990; 14: 791795.
  • 21
    Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 1997; 54: 10311037.
  • 22
    Mandoki MW, Tapia M, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol. Bull. 1997; 33: 149154.
  • 23
    Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 2001; 40: 762772.
  • 24
    Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 2002; 41: 12051215.
  • 25
    Wagner KD, Ambrosini P, Rynn M et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 10331041.
  • 26
    Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am. J. Psychiatry 2004; 161: 10791083.
  • 27
    Emslie G, Wagner KD, Kutcher S et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 2006; 45: 709719.
  • 28
    Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J. Child Adolesc. Psychopharmacol. 2006; 16: 5975.
  • 29
    von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J. Clin. Psychopharmacol. 2006; 26: 311315.
  • 30
    Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J. Am. Acad. Child Adolesc. Psychiatry 2006; 45: 280288.
  • 31
    March J, Silva S, Petrycki S et al. Fluoxetine, cognitive–behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807820.
  • 32
    Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J. Am. Acad. Child Adolesc. Psychiatry 2007; 46: 479488.
  • 33
    Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J. Am. Acad. Child Adolesc. Psychiatry 2009; 48: 721729.
  • 34
    Raz A. Perspectives on the efficacy of antidepressants for child and adolescent depression. PLoS Med. 2006; 3: 3541.
  • 35
    Hetrick SE, Merry S, McKenzie J, Sindahl P, Proctor M. Serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst. Rev. 2007; 3: CD004851.
  • 36
    Cheung AH, Emslie GJ, Mayes TL. The use of antidepressants to treat depression in children and adolescents. CMAJ 2006; 174: 193200.
  • 37
    Bridge JA, Iyengar S, Salary CB et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 16831696.
  • 38
    U.S. Food and Drug Administration. New Pediatric Labeling Information Database – Detail. Fluoxetine. Silver Spring, MD: FDA, 2003. Available from: http://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?sd=labelingdatabase&id=BE1FD14F9F286997E040A8C0744D54EE&rownum=360 [accessed November 2013].
  • 39
    U.S. Food and Drug Administration. New Drug Application (NDA) Efficacy Supplements Calendar Year Approvals: 2009. Silver Spring, MD: FDA, 2009. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ucm215927.htm [accessed November 2013].
  • 40
    Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med 2008; 20: 7381.
  • 41
    Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am. J. Psychiatry 2009; 166: 4249.
  • 42
    Emslie GJ. Clinical guidelines versus clinical trials. J. Child Adolesc. Psychopharmacol. 2004; 14: 57.
  • 43
    Woldu H, Porta G, Goldstein T et al. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J. Am. Acad. Child Adolesc. Psychiatry 2011; 50: 490498.
  • 44
    Myles PS, Gin T. Statistical Methods for Anaesthesia and Intensive Care. Oxford: Butterworth-Heinemann, 2000.
  • 45
    Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879883.
  • 46
    Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br. J. Psychiatry 2008; 193: 1017.
  • 47
    Hetrick SE, McKenzie JE, Merry SN. The use of SSRIs in children and adolescents. Curr. Opin. Psychiatry 2010; 23: 5357.
  • 48
    Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published verses unpublished data. Lancet 2004; 363: 13411345.
  • 49
    Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch. Gen. Psychiatry 2012; 69: 572579.
  • 50
    Carroll BJ. Suicide risk and efficacy of antidepressant drugs. JAMA Psychiatry 2013; 70: 123124.
  • 51
    Spielmans GI, Jureidini J, Healy D, Purssey R. Inappropriate data and measures lead to questionable conclusions. JAMA Psychiatry 2013; 70: 121122.
  • 52
    Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. JAMA 1998; 279: 10891093.
  • 53
    Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit E. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J. Am. Acad. Child Adolesc. Psychiatry 2006; 45: 11511161.
  • 54
    March J, Silva S, Petrycki S et al. The Treatment for Adolescents with Depression Study (TADS); long-term effectiveness and safety outcomes. Arch. Gen. Psychiatry 2007; 64: 11321144.
  • 55
    Dubicka B, Elvins R, Roberts C, Chick G, Wilkinson P, Goodyer IM. Combined treatment with cognitive–behavioural therapy in adolescent depression: meta-analysis. Br. J. Psychiatry 2010; 197: 433440.
  • 56
    Brent D, Emslie G, Clarke G et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized trial. JAMA 2008; 299: 901913.
  • 57
    Emslie GJ, Mayes T, Porta G et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am. J. Psychiatry 2010; 167: 782791.
  • 58
    Emslie GJ, Kennard BD, Mayes TL et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am. J. Psychiatry 2008; 165: 459467.
  • 59
    Emslie GJ, Heiligenstein JH, Hoog SL et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 2004; 43: 13971405.
  • 60
    Kennard BD, Emslie GJ, Mayes TL et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J. Am. Acad. Child Adolesc. Psychiatry 2008; 47: 13951404.
  • 61
    Weissman MM, Gammon GD, John K et al. Children of depressed parents. Increased psychopathology and early onset of major depression. Arch. Gen. Psychiatry 1987; 44: 847853.
  • 62
    Gunlicks ML, Weissman MM. Change in child psychopathology with improvement in parental depression: a systematic review. J. Am. Acad. Child Adolesc. Psychiatry 2008; 47: 379389.
  • 63
    Weissman MM, Pilowsky DJ, Wickramaratne PJ et al. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA 2006; 295: 13891398.
  • 64
    Pilowsky DJ, Wickramaratne P, Talati A et al. Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am. J. Psychiatry 2008; 165: 11361147.
  • 65
    Cheung AH, Zuckerbrot RA, Jensen PS et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 2007; 120: e13131326.
  • 66
    beyondblue. Clinical practice guidelines: Depression in children and young adults. Melbourne: beyondblue: the national depression initiative, 2010.
  • 67
    National Institute for Health and Clinical Excellence. Depression in children and young people: identification and management in primary, community and secondary care. Leicester, UK: British Psychological Society, 2005.
  • 68
    Wisniewski S, Rush A, Nierenberg A et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR* D report. Am. J. Psychiatry 2009; 166: 599607.
  • 69
    Tonge BJ, Gordon MS, Melvin GA. Treating depression in the developmentally disabled: intellectual disability and pervasive developmental disorders. In: Rey JM, Birmaher B, eds. Treating Child and Adolescent Depression. Philadephia: Lippincott Williams & Wilkins, 2009; 310320.
  • 70
    Seligman EP. Afterword – a plea. In: Nathan PE, Gorman JM, eds. A Guide to Treatments that Work. New York: Oxford University Press, 1998; 558571.